Morphologic and Molecular Heterogeneity of High-grade Serous Carcinoma Precursor Lesions.

"Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article."

"Supported by the Break Through Cancer (BTC-IOC), the Richard W. TeLinde Endowment from the Johns Hopkins University, NIH/NCI (U2CCA271891, P50CA228991, R01CA260628, and R01CA215483). C.D. is a consultant to Exact Sciences and has been paid in equity and income. C.D. is a founder of Belay Diagnostics. C.D. is an inventor of some technologies. The companies named above as well as other companies have licensed previously described technologies related to the work described in this paper from Johns Hopkins University. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors as well as Johns Hopkins University. The terms of all of these arrangements are being managed by Johns Hopkins University in accordance with its conflict of interest policies."